Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	378.70M +34.3%
Revenue (ttm)	n/a
Net Income	-76.25M
EPS	-0.67
Shares Out	126.87M
PE Ratio	n/a
Forward PE	11.71
Dividend	n/a
Ex-Dividend Date	n/a

Volume	369,371
Average Volume	698,819
Open	3.035
Previous Close	2.985
Day's Range	2.955 - 3.055
52-Week Range	2.530 - 5.230
Beta	0.87
RSI	56.42
Earnings Date	May 12, 2026

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE